Sunday, July 3, 2011

Laying to rest the Emerging Markets wildebeest

While the greatly eroded wealth in Banks in 2009 and that taking place now in Europe continues to take its toll., the world’s pecking order has changed. The Emerging Markets have become the Developed Markets and vice versa. Thus the 56% vote in IMF that Europe and Us hold may well become the distressed majority while the remaining 44% with most likely a Chinese Dy managing Director in tow become the growing minority dissident vote or so some thought. china and US rallied behind the lady Lagarde and DSK is finally out with poll propaganda a much more credible presidential candidate

While global governance is at best a fig leaf for a shaky foundation of war mongering (NATO), Modern revolution ( Iraq, Egypt, Syria )  and the atrocites in Afghanistan and inner Mongolia/north western China cannot be equated, there is a surfeit of mediocrity being paid in flowin rivers of indonesian Rupiah, Mexican Pesos, Brazilian Riais and even in new look Indian Rupees, that survives on browbeating discipline, sucking upto politicians and spending solely from their salary account. For this majority, the term global professionals has histrionically been applied by us in the reform business, thinking we have our big bucks safeguarded by the salaried majority. But the salaried majority much like the developed nations of the last millenium, stagnate, run distress valuations on their and their local retailer’s franchise and have much gutter cleaning to avoid and postpone to partake of real work. Not the rambling about the crisis surely, my regular readers will ask. And they will be right..As friends of entrepreneurs as passers on of classified and confidential information and more respectably as career bureaucrats, these salaried pros have survived on either their own bonus or cribbing about the others’ bonuses for a long time.

Asking them to take stock, as part of their pay or as their duty is akin to inviting bulls to your own china shop as they detest and loathe reason, getting deserving passes to come into business homes and flailing students hostels and destroy their family lives for a peaceful Sunday and Weekend. As a professional i have seen many such colleagues and have enjoyed the 5 day work week to the hilt engaging myself in traveling, treating my investment banking career as a sure hobby and not much else, and working out deals with more than 5-10 rudimentary failures to assess and partake of the present and its business models, as also multiple failures to appreciate that there work without such lacunae could make a meaningful device. Thus, the greater part of my world has become the growing dark abyss of It support and Business Process Transformation, an industry worth $200 bln with India’s 1/3 share and that of the top 4 management consultants even greater. However, those in that sector have no out anymore and they should not fool themselves as these products and the consultants supporting them have become part of the legacy tree which will keep bearing fruit forever, infinitely better than any bailout but not much more for anyone

The other equal abysses to choose from like Infrastructure, construction bubbles with its arcane desire for a 20% uptick every other year and the never growing cottage industry of education also remain good avenues for the fools in government to fool those not in government. But healthcare has somehow crossed the rubicon.

Helped by the efforts of NGOs like the GAVI alliance in Africa and Asia, the gaps in medicine and the frequent returns for innovation from healthcare research companies show a desire in the market to watch growth fructify gainfully.  also recent cost cutting efforts at Pfizer and Glaxo show that apart from Growth even the big 4 in the industry are ready to embrace a lower cost model and even the Affordable Care act with its many compromises may see success in the near term.

Wednesday, April 27, 2011

The New round of Quantitative Easing

As jobs start to get back into the economy, stability is still a long way away and the Ed is unlikely to start raising rates too soon, instead use the money from sold investments/junk to buy more liquidity for the Us and thence the world is to get more easy money flows to keep propping growth till the inflation pop gets someone too squeamish

in reference to:

"S. | Asia | Europe | Wires Did the Fed Just Tip Its Hand To a Third Round of Easing? With a subtle wave of his baton, the second coming of the Maestro may have started the music for another round of Federal Reserve monetary easing. Fed Members Agree to Keep Stimulus Plan, Low Rates"
- Did Fed Just Tip Hand to Third Round of Easing? - CNBC (view on Google Sidewiki)

Tuesday, April 19, 2011

YES BANK results are in

as usual trading room is buzzing and index has moved up anotch

in reference to: Editing a post - Posterous (view on Google Sidewiki)

J&J and Novartis get help from a large cash outgo as they report good , better and better results

Novartis spent $51 billion in Alcon to add $1.9 billion sales in the current 2011 quarter, J&J managed to improve earnings to close to $3.77 billion excluding litigation costs to $1.35 per share while counterbalancing its medical device revenues of $2 billion with a pitch for Synthes. Core Earnings at Novartis were up to $1.41 per share despite sales lowerby $1.1 billion in anti-flu sales and more expected in reducing Diovan

Constant currency sales at Novartis topped $14 billion and J&J sales topped $16.1 billion. International sales were mostly responsible for the J&J recovery at 7% up tickLe siège social de Johnson & Johnson à New Bru...Image via Wikipedia

Write text here...

Friday, February 4, 2011

AETNA reports better profits and large dividend

WASHINGTON - MARCH 4:   Aetna Chairman, CEO & ...Image by Getty Images via @daylife

Aetna Reports Fourth-Quarter and Full-Year 2010 Results


  • Fourth-quarter 2010 operating earnings per share(1) were $.63; compared to the Thomson-First Call mean of $.62
  • Full-year 2010 operating earnings per share were $3.68; compared to the Thomson-First Call mean of $3.65
  • Net income per share was $.53 for the fourth quarter 2010 and $4.18 for the full year
  • Commercial medical benefit ratio was 80.7 percent in the fourth quarter 2010 and 80.6 percent for the full year 2010
  • Medical membership totaled 18.5 million members at December 31, 2010
  • Company declares quarterly dividend of $.15 per share
  • Aetna projects full-year 2011 operating earnings per share of $3.70 to $3.80(2)
Related Documents

4Q10 Financial Supplement (PDF: 65 KB / 17 pages)

Guidance Summary (PDF: 21 KB / 3 pages)

HARTFORD, Conn., February 04, 2011 — Aetna (NYSE: AET) today announced fourth-quarter
2010 operating earnings(1) of $255.0 million, or $.63 per share, a per share increase of 58 percent
over 2009. Full-year 2010 operating earnings were $1.6 billion, or $3.68 per share, a per share
increase of 34 percent over 2009. The increase in both the fourth quarter and full-year 2010 operating
earnings were largely the result of higher Commercial underwriting margins driven by management
actions to appropriately price the business, and lower utilization, as well as a reduced number of shares
outstanding, partially offset by lower Commercial Insured membership. Full-year 2010 operating
earnings also reflect favorable prior-period reserve development. Net income for the fourth quarter was
$215.6 million, or $.53 per share, including $.10 per share of net realized capital gains and other items.
Full-year net income was $1.8 billion, or $4.18 per share, a per share increase of 47 percent over 2009.
4Q10
"Aetna's strong operating results in 2010 demonstrate the significant performance

improvement we have made by remaining disciplined while focusing on customer

needs," said Ronald A. Williams, chairman. "As it becomes even more imperative to

address quality and affordability in health care, Aetna will play an increasingly important

role. I am confident that we are well-positioned with the right management team and

long-term strategy to capitalize on the domestic and global opportunities in health care."

"Our company's success, as always, is centered on creating value for our customers

by offering innovative products and services that improve quality and help manage costs

through integrated benefit designs and member engagement," said Mark T. Bertolini, CEO

and president. "Even as we continue to navigate through a difficult economy, we are squarely

focused on making investments in our business that can help meet the needs of current and

future customers."


(from an updown.com video report link) Health insurer Aetna (AET) posted fourth quarter earnings of $215.6 million, or $0.53 per share today, compared to $165.9 million, or $0.38 per share, in the same quarter last year. Operating earnings of $0.63 per share were just ahead of analyst expectations. Revenue dipped 2%, to $8.5 billion. Aetnas earnings expectations of $3.70 to $3.80 per share for 2011 are well ahead of analyst forecasts. The company also said it is moving to a quarterly dividend program, and its first quarterly dividend will be $0.15 per share, paid in April. Its latest annual dividend of $0.04 per share was paid in November. Also today, pharmaceutical services company AmerisouceBergen (ABC) posted fiscal first quarter earnings of $160.5 million, or $0.57 per share, compared to $151.3 million, or $0.52 per share, in the same quarter last year. Revenue grew by about 3%, to $19.89 billion. Results were just ahead of analyst expectations. AmerisourceBergen said it expects to earn $2.31 to $2.41 per share in 2011, while analysts are looking for about $2.38 per share. For MarketNewsVideo.com, Im Sayoko Murase.


Friday, October 29, 2010

Merck reports a Titanic disaster (ongoing)

RofecoxibImage via Wikipedia


Reuters Q3 report

Merck & Co Inc reported disappointing quarterly sales and took an almost $1 billion charge related to a previously disclosed U.S. government probe of its recalled Vioxx arthritis drug, sending its shares 2.1 percent lower.

Merck (MRK.N), like most big U.S. drugmakers in the third quarter, beat profit forecasts on Friday even though its sales fell short, as results were bolstered by cost cuts or other factors. And as with its rivals, investors seemed to pay greater heed to the sales disappointment.

"The third quarter featured slightly lighter revenues, better expenses and better tax rate," said Credit-Suisse analyst Catherine Arnold of Merck's results, describing them as a "low quality beat" because of the sales shortfall.

The earnings report includes an array of drugs and consumer products acquired through the company's purchase last November of New Jersey rival Schering-Plough.

Global revenue almost doubled to $11.12 billion in the quarter. But that was shy of the average Wall Street forecast of $11.24 billion.

Analysts said growth of arthritis drug Remicade, acquired in the Schering-Plough merger, was weaker than expected due in part to price pressures in Europe.

Third-quarter earnings of the combined company fell 89 percent to $372 million, or 11 cents per share, reflecting merger charges and a charge for setting aside a $950 million Vioxx legal reserve.

The charge relates to an ongoing probe by U.S. prosecutors in Massachusetts of how Merck had marketed Vioxx -- Merck's onetime blockbuster arthritis drug that was recalled in 2004 after being linked to heart risks.


Charlie Chaplin stands on Douglas Fairbanks' s...Image via WikipediaRelated articles
Merck's Earnings Slump On Cost Of Digesting Schering (forbes.com)
Enhanced by Zemanta

Saturday, October 23, 2010

Amylin loses the plot

Source: FDA-OCIImage via WikipediaByetta producer and Eli Lily partner suffered a drop in its byetta sales , lower by $150 mn for Q3 as its new version of the Byetta regimen, Bydureon was rejected by the FDA for possible Cardiac complications. For FDA it might even have been a simpler case of making a public monkey out of Amylin after Avandia and Glaxo Smithkline was destroyed because of inadequate disclosure on its Cardiac side effects and a recall spanning a loss of $198 mln in September 2010.

Even as diabetes medication comes under the scanner and Pfizer goes ahead with a new sign up with India's Biocon, pecuniary FDA action seems to have triggered an interesting deal mania intth e industry wih Eli Lily rumored to be in the running for using its $5.6 billion in cash to buy up Amylin which is 33% cheaper at $2.5 bln this week or other such niche producers with a pipeline of promising new molecules in its belt.


Enhanced by Zemanta